Pacira BioSciences (PCRX) Revenue & Revenue Breakdown
Pacira BioSciences Revenue Highlights
Latest Revenue (Y)
$674.98M
Latest Revenue (Q)
$178.02M
Main Segment (Y)
Product
Pacira BioSciences Revenue by Period
Pacira BioSciences Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $674.98M | 1.22% |
| 2022-12-31 | $666.82M | 23.14% |
| 2021-12-31 | $541.53M | 28.68% |
| 2020-12-31 | $420.83M | -0.05% |
| 2019-12-31 | $421.03M | 24.83% |
| 2018-12-31 | $337.28M | 17.67% |
| 2017-12-31 | $286.63M | 3.71% |
| 2016-12-31 | $276.37M | 10.99% |
| 2015-12-31 | $249.00M | 25.97% |
| 2014-12-31 | $197.67M | 131.05% |
| 2013-12-31 | $85.55M | 118.89% |
| 2012-12-31 | $39.08M | 149.12% |
| 2011-12-31 | $15.69M | 7.74% |
| 2010-12-31 | $14.56M | -2.96% |
| 2009-12-31 | $15.01M | 7.76% |
| 2008-12-31 | $13.93M | - |
Pacira BioSciences generated $674.98M in revenue during NA 2023, up 1.22% compared to the previous quarter, and up 200.13% compared to the same period a year ago.
Pacira BioSciences Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $178.02M | 6.53% |
| 2024-03-31 | $167.12M | -7.79% |
| 2023-12-31 | $181.24M | 10.56% |
| 2023-09-30 | $163.93M | -3.27% |
| 2023-06-30 | $169.47M | 5.69% |
| 2023-03-31 | $160.34M | -6.75% |
| 2022-12-31 | $171.96M | 2.68% |
| 2022-09-30 | $167.47M | -1.15% |
| 2022-06-30 | $169.41M | 7.23% |
| 2022-03-31 | $157.99M | -0.76% |
| 2021-12-31 | $159.19M | 24.64% |
| 2021-09-30 | $127.72M | -5.80% |
| 2021-06-30 | $135.59M | 13.92% |
| 2021-03-31 | $119.03M | -7.41% |
| 2020-12-31 | $128.55M | 9.42% |
| 2020-09-30 | $117.48M | 55.60% |
| 2020-06-30 | $75.50M | -28.56% |
| 2020-03-31 | $105.68M | -13.67% |
| 2019-12-31 | $122.42M | 16.95% |
| 2019-09-30 | $104.69M | 2.03% |
| 2019-06-30 | $102.60M | 12.37% |
| 2019-03-31 | $91.31M | -4.00% |
| 2018-12-31 | $95.11M | 13.98% |
| 2018-09-30 | $83.45M | -0.78% |
| 2018-06-30 | $84.11M | 12.73% |
| 2018-03-31 | $74.61M | -5.65% |
| 2017-12-31 | $79.08M | 17.44% |
| 2017-09-30 | $67.33M | -5.07% |
| 2017-06-30 | $70.93M | 2.38% |
| 2017-03-31 | $69.28M | -4.96% |
| 2016-12-31 | $72.90M | 6.65% |
| 2016-09-30 | $68.36M | -1.85% |
| 2016-06-30 | $69.64M | 6.36% |
| 2016-03-31 | $65.47M | -5.55% |
| 2015-12-31 | $69.32M | 11.43% |
| 2015-09-30 | $62.21M | 5.18% |
| 2015-06-30 | $59.15M | 1.43% |
| 2015-03-31 | $58.32M | -5.63% |
| 2014-12-31 | $61.79M | 18.72% |
| 2014-09-30 | $52.05M | 10.35% |
| 2014-06-30 | $47.16M | 28.65% |
| 2014-03-31 | $36.66M | 9.23% |
| 2013-12-31 | $33.56M | 44.31% |
| 2013-09-30 | $23.26M | 35.69% |
| 2013-06-30 | $17.14M | 47.93% |
| 2013-03-31 | $11.59M | 10.88% |
| 2012-12-31 | $10.45M | 23.14% |
| 2012-09-30 | $8.49M | -31.25% |
| 2012-06-30 | $12.34M | 58.18% |
| 2012-03-31 | $7.80M | 84.36% |
| 2011-12-31 | $4.23M | 7.00% |
| 2011-09-30 | $3.96M | 8.80% |
| 2011-06-30 | $3.64M | -5.88% |
| 2011-03-31 | $3.86M | 76.31% |
| 2010-12-31 | $2.19M | -51.65% |
| 2010-09-30 | $4.53M | 48.35% |
| 2010-06-30 | $3.06M | -36.14% |
| 2010-03-31 | $4.78M | 11.67% |
| 2009-12-31 | $4.28M | 13.94% |
| 2009-09-30 | $3.76M | - |
Pacira BioSciences generated $178.02M in revenue during Q2 2024, up 6.53% compared to the previous quarter, and up 111.03% compared to the same period a year ago.
Pacira BioSciences Revenue Breakdown
Pacira BioSciences Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Bupivacaine Liposome Injectable Suspension | $3.34M | $6.48M | $3.61M | - | - |
| ZILRETTA | $111.10M | $105.52M | $12.68M | - | - |
| Product | $672.25M | $664.15M | $426.61M | - | - |
| EXPAREL | $538.12M | $536.90M | $506.51M | - | - |
| Royalty | - | - | - | $3.03M | - |
| EXPAREL/bupivacaine liposome injectable suspension | - | - | - | - | $411.03M |
| DepoCyte | - | - | - | - | - |
Pacira BioSciences's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (50.74%), EXPAREL (40.62%), ZILRETTA (8.39%), and Bupivacaine Liposome Injectable Suspension (0.25%).
Quarterly Revenue by Product
| Product/Service | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bupivacaine Liposome Injectable Suspension | $3.15M | $2.52M | $1.10M | $858.00K | $695.00K | $688.00K | $1.01M | $2.96M | $956.00K | $1.56M | - | - | - | - | - | - | - | - | - | - |
| ZILRETTA | $30.71M | $25.84M | $28.70M | $28.80M | $29.26M | $24.33M | $27.97M | $26.49M | $27.42M | $23.64M | - | - | - | - | - | - | - | - | - | - |
| EXPAREL | $136.85M | $132.43M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Product | $176.39M | $165.82M | $179.76M | $163.58M | $169.47M | $159.43M | $171.59M | $166.56M | $168.58M | $157.42M | $126.79M | $134.86M | $118.74M | $129.76M | $116.89M | $75.22M | $104.75M | $121.85M | $104.35M | $101.82M |
| EXPAREL/bupivacaine liposome injectable suspension | - | - | - | $128.67M | $135.13M | $130.41M | $132.64M | $137.01M | $129.21M | $115.47M | - | - | - | - | - | - | - | - | - | - |
| Royalty | - | - | - | - | - | - | - | - | - | - | $931.00K | $602.00K | $1.21M | $595.00K | $289.00K | $939.00K | $578.00K | $335.00K | $780.00K | - |
| Collaborative Licensing and Milestone Revenue | - | - | - | - | - | - | - | - | - | - | - | $125.00K | - | - | - | - | - | - | - | - |
Pacira BioSciences's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: Product (50.82%), EXPAREL (39.43%), ZILRETTA (8.85%), and Bupivacaine Liposome Injectable Suspension (0.91%).
Pacira BioSciences Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| RDY | Dr. Reddy's Laboratories | $279.16B | - |
| ALKS | Alkermes | $1.66B | $378.14M |
| PBH | Prestige Consumer Healthcare | $1.13B | $267.14M |
| PAHC | Phibro Animal Health | $977.89M | $263.22M |
| HCM | HUTCHMED (China) | $838.00M | $152.56M |
| PCRX | Pacira BioSciences | $674.98M | $178.02M |
| COLL | Collegium Pharmaceutical | $566.77M | $144.92M |
| ANIP | ANI Pharmaceuticals | $486.82M | $138.04M |
| ITCI | Intra-Cellular Therapies | $462.18M | $175.38M |
| EGRX | Eagle Pharmaceuticals | $316.61M | $64.65M |
| DCPH | Deciphera Pharmaceuticals | $163.36M | $45.00M |
| SSIC | Silver Spike Investment | $11.72M | $2.76B |
| IXHL | Incannex Healthcare | - | - |
PCRX Revenue FAQ
What is Pacira BioSciences’s yearly revenue?
Pacira BioSciences's yearly revenue for 2023 was $674.98M, representing an increase of 1.22% compared to 2022. The company's yearly revenue for 2022 was $666.82M, representing an increase of 23.14% compared to 2021. PCRX's yearly revenue for 2021 was $541.53M, representing an increase of 28.68% compared to 2020.
What is Pacira BioSciences’s quarterly revenue?
Pacira BioSciences's quarterly revenue for Q2 2024 was $178.02M, a 6.53% increase from the previous quarter (Q1 2024), and a 5.05% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $167.12M, a -7.79% decrease from the previous quarter (Q4 2023), and a 4.23% increase year-over-year (Q1 2023). PCRX's quarterly revenue for Q4 2023 was $181.24M, a 10.56% increase from the previous quarter (Q3 2023), and a 5.40% increase year-over-year (Q4 2022).
What is Pacira BioSciences’s revenue growth rate?
Pacira BioSciences's revenue growth rate for the last 3 years (2021-2023) was 24.64%, and for the last 5 years (2019-2023) was 60.32%.
What are Pacira BioSciences’s revenue streams?
Pacira BioSciences's revenue streams in c 23 are Bupivacaine Liposome Injectable Suspension, ZILRETTA, Product, and EXPAREL. Bupivacaine Liposome Injectable Suspension generated $3.34M in revenue, accounting 0.25% of the company's total revenue, down -48.39% year-over-year. ZILRETTA generated $111.1M in revenue, accounting 8.39% of the company's total revenue, up 5.29% year-over-year. Product generated $672.24M in revenue, accounting 50.74% of the company's total revenue, up 1.22% year-over-year. EXPAREL generated $538.12M in revenue, accounting 40.62% of the company's total revenue, up 0.23% year-over-year.
What is Pacira BioSciences’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Pacira BioSciences was Product. This segment made a revenue of $672.24M, representing 50.74% of the company's total revenue.